Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.
IPO Year: 2021
Exchange: NASDAQ
Website: https://www.exscientia.ai
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/9/2024 | Buy | TD Cowen | |
| 1/5/2024 | $11.00 → $9.00 | Buy → Neutral | BofA Securities |
TD Cowen initiated coverage of Exscientia plc with a rating of Buy
BofA Securities downgraded Exscientia plc from Buy to Neutral and set a new price target of $9.00 from $11.00 previously